This week in health equity and access: Medicaid cuts; mailed FIT outreach; EEOC pregnancy rules; GLP-1 Bridge access; and 2027 policy shifts.

In this Q&A, Rob Stransky of NiceRx explains how to screen patients for gray-market retatrutide use and why cost drives demand for unregulated peptides.

After Pennsylvania began rewarding Medicaid managed care plans for increasing well-child visits among Black infants, rates did not change significantly overall but varied by region.

A study of 132 patients with AML given venetoclax-based therapy, 10 profiled by single-cell sequencing, linked immune features to treatment response.

Six studies found liver transplant disparities by insurance, region, ethnicity, and sex, plus links between unmet social needs and frailty in cirrhosis.

Liver disease disparities tied to insurance and race spanned HCC surveillance, transplant listing, and drug access in data at The Liver Meeting 2026.

GOLD leaders say COPD is diagnosed too late and its smoking-only image is outdated, and the 2027 report puts rehab and non–drug care up front.

Most patients with CLL/SLL who discontinued a first-line BTK inhibitor did not start second-line therapy, and older age was linked to worse outcomes.